Literature DB >> 7821388

Specific patterns of defective HSV-1 gene transfer in the adult central nervous system: implications for gene targeting.

M J Wood1, A P Byrnes, M G Kaplitt, D W Pfaff, S D Rabkin, H M Charlton.   

Abstract

Viral vectors are a means by which genes can be delivered to specific sites in the adult central nervous system. Nevertheless, the interaction between the viral vector and cells of the nervous system, which forms the basis for specific gene transfer, is not well understood. In this study a nonreplicating defective herpes simplex virus type 1 vector, expressing the marker gene lacZ, was stereotaxically injected at varying titers into the rat central nervous system. Three sites were targeted: the caudate nucleus, dentate gyrus, and cerebellar cortex, and the resulting patterns of beta-galactosidase activity were examined. Many cells of neuronal and glial morphology, and of differing neuronal subtypes, expressed beta-galactosidase at each of the injection sites. However, beta-galactosidase activity was also detected in distant secondary brain areas, the neurons of which make afferent connections with the primary sites. This strongly suggested that the retrograde transport of defective virus was the basis for the enzyme activity observed at a distance. Moreover, retrograde transport to secondary sites was found to be highly selective and restricted to certain retrograde neuroanatomical pathways in a specific and titer dependent fashion. The pathways observed were predominantly, but not exclusively, monoaminergic in origin. This finding is supported by reports of specific tropism by HSV for monoaminergic circuits in experimental encephalitis and transneuronal tracing studies. Our observations suggest that certain functional neuronal populations, which are permissive for the retrograde transfer of defective HSV-1 vectors, might be specifically targeted for gene transfer using this approach. Conversely, a knowledge of the pathways permissive for viral uptake, retrograde transfer, and subsequent gene expression will be essential in order to predict the consequences of gene transfer using viral vectors.

Entities:  

Mesh:

Year:  1994        PMID: 7821388     DOI: 10.1006/exnr.1994.1192

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  6 in total

1.  Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo.

Authors:  C E Lilley; F Groutsi; Z Han; J A Palmer; P N Anderson; D S Latchman; R S Coffin
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 2.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

3.  Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector.

Authors:  U Blömer; L Naldini; T Kafri; D Trono; I M Verma; F H Gage
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

4.  Immunological instability of persistent adenovirus vectors in the brain: peripheral exposure to vector leads to renewed inflammation, reduced gene expression, and demyelination.

Authors:  A P Byrnes; R E MacLaren; H M Charlton
Journal:  J Neurosci       Date:  1996-05-01       Impact factor: 6.167

5.  Overexpression of 5-HT1B receptor in dorsal raphe nucleus using Herpes Simplex Virus gene transfer increases anxiety behavior after inescapable stress.

Authors:  Michael S Clark; Timothy J Sexton; Molly McClain; Daniel Root; Ruth Kohen; John F Neumaier
Journal:  J Neurosci       Date:  2002-06-01       Impact factor: 6.167

6.  A limited innate immune response is induced by a replication-defective herpes simplex virus vector following delivery to the murine central nervous system.

Authors:  Zane Zeier; J Santiago Aguilar; Cecilia M Lopez; G B Devi-Rao; Zachary L Watson; Henry V Baker; Edward K Wagner; David C Bloom
Journal:  J Neurovirol       Date:  2009-09       Impact factor: 2.643

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.